Celldex Therapeutics (CLDX) Competitors $26.77 -0.77 (-2.80%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$26.34 -0.43 (-1.61%) As of 10/10/2025 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDX vs. ALKS, LGND, FOLD, MNKD, NVAX, BCRX, OPK, DVAX, INVA, and ZBIOShould you be buying Celldex Therapeutics stock or one of its competitors? The main competitors of Celldex Therapeutics include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Amicus Therapeutics (FOLD), MannKind (MNKD), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), OPKO Health (OPK), Dynavax Technologies (DVAX), Innoviva (INVA), and Zenas BioPharma (ZBIO). These companies are all part of the "biotechnology" industry. Celldex Therapeutics vs. Its Competitors Alkermes Ligand Pharmaceuticals Amicus Therapeutics MannKind Novavax BioCryst Pharmaceuticals OPKO Health Dynavax Technologies Innoviva Zenas BioPharma Alkermes (NASDAQ:ALKS) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk. Is ALKS or CLDX more profitable? Alkermes has a net margin of 23.15% compared to Celldex Therapeutics' net margin of -3,446.88%. Alkermes' return on equity of 24.86% beat Celldex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Alkermes23.15% 24.86% 17.14% Celldex Therapeutics -3,446.88%-27.61%-26.20% Do analysts rate ALKS or CLDX? Alkermes presently has a consensus target price of $42.00, suggesting a potential upside of 34.57%. Celldex Therapeutics has a consensus target price of $46.13, suggesting a potential upside of 72.30%. Given Celldex Therapeutics' higher probable upside, analysts plainly believe Celldex Therapeutics is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 0 Sell rating(s) 3 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 2.93Celldex Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do institutionals & insiders believe in ALKS or CLDX? 95.2% of Alkermes shares are owned by institutional investors. 4.4% of Alkermes shares are owned by insiders. Comparatively, 4.4% of Celldex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, ALKS or CLDX? Alkermes has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500. Comparatively, Celldex Therapeutics has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Which has preferable valuation & earnings, ALKS or CLDX? Alkermes has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.56B3.31$367.07M$2.0815.00Celldex Therapeutics$7.02M253.25-$157.86M-$3.01-8.89 Does the media refer more to ALKS or CLDX? In the previous week, Alkermes and Alkermes both had 4 articles in the media. Celldex Therapeutics' average media sentiment score of 0.89 beat Alkermes' score of 0.65 indicating that Celldex Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAlkermes beats Celldex Therapeutics on 11 of the 15 factors compared between the two stocks. Get Celldex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDX vs. The Competition Export to ExcelMetricCelldex TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.83B$3.38B$6.10B$10.63BDividend YieldN/A2.29%5.67%4.71%P/E Ratio-8.8921.9785.2726.57Price / Sales253.25462.21612.78132.59Price / CashN/A47.2238.5062.09Price / Book2.3810.2112.726.53Net Income-$157.86M-$52.40M$3.30B$275.96M7 Day Performance1.36%0.88%0.89%-0.77%1 Month Performance6.23%10.41%6.29%3.67%1 Year Performance-14.53%27.28%80.41%37.30% Celldex Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDXCelldex Therapeutics2.2312 of 5 stars$26.77-2.8%$46.13+72.3%-9.8%$1.83B$7.02M-8.89150Analyst ForecastALKSAlkermes4.3511 of 5 stars$30.99-0.2%$42.00+35.5%+14.0%$5.13B$1.56B14.901,800LGNDLigand Pharmaceuticals3.9005 of 5 stars$182.61+0.9%$176.50-3.3%+77.2%$3.55B$167.13M-45.6580News CoverageAnalyst ForecastFOLDAmicus Therapeutics4.4904 of 5 stars$8.16-0.5%$15.78+93.4%-17.4%$2.53B$528.29M-67.99480Analyst ForecastAnalyst RevisionMNKDMannKind4.0138 of 5 stars$5.66-1.7%$11.17+97.3%-22.8%$1.77B$301.74M51.46400News CoverageAnalyst ForecastNVAXNovavax4.2311 of 5 stars$9.08-4.0%$14.29+57.3%-35.5%$1.54B$682.16M3.981,990Analyst ForecastBCRXBioCryst Pharmaceuticals4.0597 of 5 stars$7.02-1.8%$16.30+132.2%+1.4%$1.50B$450.71M-39.00530Analyst ForecastOPKOPKO Health4.2111 of 5 stars$1.58+1.3%$2.63+66.1%+2.7%$1.24B$713.10M-6.322,997Analyst ForecastDVAXDynavax Technologies4.4753 of 5 stars$10.14+0.4%$24.33+140.0%-3.1%$1.18B$277.25M-22.04350Positive NewsAnalyst ForecastINVAInnoviva4.7664 of 5 stars$17.42-0.3%$37.60+115.8%-11.0%$1.10B$358.71M56.20100Analyst ForecastZBIOZenas BioPharma2.4396 of 5 stars$23.03+5.8%$36.67+59.2%N/A$916.32M$5M-6.49N/ATrending NewsAnalyst ForecastInsider TradeAnalyst RevisionGap Up Related Companies and Tools Related Companies Alkermes Alternatives Ligand Pharmaceuticals Alternatives Amicus Therapeutics Alternatives MannKind Alternatives Novavax Alternatives BioCryst Pharmaceuticals Alternatives OPKO Health Alternatives Dynavax Technologies Alternatives Innoviva Alternatives Zenas BioPharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLDX) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Celldex Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Celldex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
